Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study-Reference-Cited by-同舟云学术

Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study

Published:2021-04 Issue:6 Volume:10 Page:509-517
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:Journal of Comparative Effectiveness Research

Author:

Kömel Pimenta Pedro Ricardo¹^ORCID,Ribeiro da Silva Michael Ruberson¹²^ORCID,Ribeiro dos Santos Jéssica Barreto¹²^ORCID,Kakehasi Adriana Maria³^ORCID,Assis Acurcio Francisco de¹³^ORCID,Alvares-Teodoro Juliana¹^ORCID

Affiliation:

1. Department of Social Pharmacy, College of Pharmacy, Federal University of Minas Gerais, President Antônio Carlos Avenue, Campus Pampulha, Belo Horizonte, Minas Gerais 6627, Brazil

2. Health Assessment, Technology & Economy Group, Center for Exact, Natural & Health Sciences, Federal University of Espírito Santo, Alto Universitário S/N, Guararema, Alegre, Espírito Santo, Brazil

3. Medicine School, Federal University of Minas Gerais, Av Prof Alfredo Balena, Belo Horizonte, Minas Gerais 190, Brazil

Abstract

Aim: To evaluate the effectiveness and safety of anti-TNF drugs for ankylosing spondylitis. Materials & methods: A prospective cohort study was performed at a pharmacy in the Brazilian Public Health System. Effectiveness by Bath Ankylosing Spondylitis Disease Activity Index, functionality by Health Assessment Questionnaire Disability Index, quality of life by European Quality of Life Five-Dimensions and safety was assessed at 6 and 12 months of follow-up. Results: About 160 patients started the treatment with adalimumab, etanercept or infliximab. There was a statistically significant improvement in disease activity, functionality and quality of life at 6 and 12 months (p < 0.05). Conclusion: This real-world study has shown that anti-TNF drugs are effective and well tolerated for ankylosing spondylitis patients.

Publisher

Future Medicine Ltd

Subject

Health Policy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cer-2020-0275

Reference31 articles.

1. Ankylosing spondylitis

2. The Seronegative Spondyloarthropathies

3. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

4. Hearing loss in ankylosing spondylitis

5. Características clínicas e frequência de polimorfismos em TLR4 em pacientes brasileiros com espondilite anquilosante

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum interα-trypsin inhibitor heavy chain H4 may be an anti-inflammatory marker reflecting disease risk, activity and treatment outcome of ankylosing spondylitis;Scandinavian Journal of Clinical and Laboratory Investigation;2023-12

2. MALT1 positively relates to Th17 cells, inflammation/activity degree, and its decrement along with treatment reflects TNF inhibitor response in ankylosing spondylitis patients;Journal of Clinical Laboratory Analysis;2022-05-27

3. Health-Related Quality of Life in Psoriatic Arthritis: Findings and Implications;Value in Health Regional Issues;2021-12